Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...

BMO Capital Markets assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note issued to ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

After hours: March 14 at 6:50:44 PM EDT Loading Chart for RNA ...

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform recommendation. Analyst Price Forecast Suggests 132.29% Upside As of March ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

One day after being the underbidder on the session topper, agents John Kimmel and Nick Sallusto were able to snag the most ...

Brook trout may have a genetic trick up their scales when it comes to adapting, with limitations, to heat waves that threaten ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

“In general, we have not recommended boosters because there is no clear evidence that people need it. But there probably is ...